Federal court gives Teva and Viatris another chance to invalidate J&J’s last patent for Invega Sustenna

John­son & John­son on­ly has one last patent cov­er­ing its long-act­ing block­buster schiz­o­phre­nia drug In­ve­ga Susten­na, and now Te­va and Vi­a­tris have an­oth­er op­por­tu­ni­ty to chal­lenge it fol­low­ing a fed­er­al cir­cuit pan­el de­ci­sion.

J&J’s Janssen unit (now J&J In­no­v­a­tive Med­i­cine) orig­i­nal­ly sued Te­va in 2018 over patent in­fringe­ment in the US Dis­trict Court of New Jer­sey in an at­tempt to pro­tect its ‘906 patent, which cov­ers the dos­ing reg­i­men. Te­va chal­lenged the va­lid­i­ty of the patent, but the court orig­i­nal­ly found that Te­va had not proven the patent was in­valid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.